¡Aprovechá el Cyber Week!
3 y 6 cuotas sin interés en toda la web
Envíos en el día a CABA y AMBA comprando antes del mediodía
¡Hola! Iniciá sesión
Inicio > Productos

Diabeto-Cardiology

$323.982,00
10% de descuento pagando con Transferencia
Ver más detalles

FORMATO

Edicion

PAPEL

Edicion

EBOOK
Descripcion
Indice
Autores
Muestra
Ficha Técnica
Descripción

Part of the renowned Braunwald family of references, Diabeto-Cardiology, 2nd Edition, provides today’s clinicians with clear, authoritative guidance on the complex challenges of providing care to patients with cardiovascular and diabetes co-morbidities. Drs. Darren K. McGuire and Nikolaus Marx, along with a leading team of experts in cardiology and diabetes, address both the foundational aspects and clinical implications for this growing number of patients, including recent breakthrough therapies and new medications that have contributed to newer and more effective treatments and improved patient outcomes. From cover to cover, this second edition offers reliable and current point-of-care coverage of the interwoven care needs of patients with these complex co-morbidities, making it an ideal resource for practitioners at all levels of experience.

  • Discusses cutting-edge therapeutic approaches to the medical care of cardiology patients with diabetes, combining coverage of the latest understanding of the complex relationship between diabetes and cardiovascular disease with recent clinical advances.
  • Offers a contemporary, clinical focus based on a new understanding of underlying pathologies, as well as application of evidence from clinical trials that have dramatically changed treatment and affected both cardiology and endocrinology practice.
  • Includes state-of-the-art coverage of antihyperglycemic medications that have demonstrated efficacy to reduce risk for atherosclerotic cardiovascular disease, heart failure, and kidney disease progression, that have affected a revolution of therapy in both cardiology and endocrinology.
  • Features a practical, concise presentation with a focus on actionable clinical content, including new Clinical Practice Points and Take Home Summaries.
  • Any additional digital ancillary content may publish up to 6 weeks following the publication date.

1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Inside Front Cover - p. iii 6. Copyright - p. iv 7. Dedication - p. v 8. Contributors - p. vii 9. Foreword - p. xi 10. Preface - p. xiii 11. Acknowledgments - p. xv 12. Braunwald’s Heart Disease Family of Books - p. xviii 13. PART I: DIABETES MELLITUS - p. P1 14. 1. Definition and Epidemiology of Type 2 Diabetes Mellitus - p. 1 15. 2. Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights - p. 9 16. 3. Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus - p. 25 17. 4. Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes - p. 48 18. 5. Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease - p. 61 19. PART II: CARDIOVASCULAR COMPLICATIONS OFTYPE 2 DIABETES - p. P81 20. 6. Epidemiology of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease - p. 81 21. 7. Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes - p. 97 22. 8. Risk Stratification Among Patients With Type 2 Diabetes With or at Risk for Atherosclerotic Cardiovascular Disease - p. 131 23. 9. Epidemiology and Pathophysiology of Heart Failure With Preserved and With Reduced Ejection Fraction in Patients With Type 2 Diabetes - p. 142 24. PART III: EFFECTS OF ANTIHYPERGLYCEMIC THERAPIES FOR TYPE 2 DIABETES ON CARDIOVASCULAR AND KIDNEY OUTCOMES - p. P151 25. 10. Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 151 26. 11. Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future - p. 170 27. 12. Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors - p. 180 28. 13. Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists - p. 193 29. 14. Antihyperglycemic Medications With Proven Cardiovascular Safety - p. 204 30. 15. Prevention of Heart Failure in People With Diabetes - p. 217 31. 16. Treatment of Patients With Reduced and With Preserved Ejection Fraction Heart Failure in Patients With Type 2 Diabetes - p. 231 32. PART IV: MANAGEMENT OF CORONARY HEART DISEASE RISK CHRONIC AND ACUTE CORONARY SYNDROMES IN PATIENTS WITH TYPE 2 DIABETES - p. P245 33. 17. Effect of Lifestyle Interventions on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 245 34. 18. Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 260 35. 19. Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes - p. 273 36. 20. Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus - p. 284 37. 21. Role of Percutaneous Coronary Intervention in Patients With Diabetes - p. 297 38. PART V: OTHER CARDIOVASCULARCONSIDERATIONS FOR PATIENTS WITH TYPE 2 DIABETES - p. P309 39. 22. Peripheral Artery Disease in Persons With Type 2 Diabetes - p. 309 40. 23. Cerebrovascular Disease in Persons With Diabetes - p. 324 41. 24. Atrial Fibrillation in Persons With Type 2 Diabetes - p. 342 42. 25. Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes - p. 353 43. 26. Disparities in Type 2 Diabetes Risk, Cardiovascular Consequences, and Care: Females, Racial/Ethnic Minorities, and the Elderly - p. 369 44. 27. The Quality Chasm and the Need for Implementation Science to Reduce Cardiovascular Disease Risk in Type 2 Diabetes - p. 381 45. Index - p. 387 46. Inside Back Cover - p. 396

Descripcion
Descripción

Part of the renowned Braunwald family of references, Diabeto-Cardiology, 2nd Edition, provides today’s clinicians with clear, authoritative guidance on the complex challenges of providing care to patients with cardiovascular and diabetes co-morbidities. Drs. Darren K. McGuire and Nikolaus Marx, along with a leading team of experts in cardiology and diabetes, address both the foundational aspects and clinical implications for this growing number of patients, including recent breakthrough therapies and new medications that have contributed to newer and more effective treatments and improved patient outcomes. From cover to cover, this second edition offers reliable and current point-of-care coverage of the interwoven care needs of patients with these complex co-morbidities, making it an ideal resource for practitioners at all levels of experience.

  • Discusses cutting-edge therapeutic approaches to the medical care of cardiology patients with diabetes, combining coverage of the latest understanding of the complex relationship between diabetes and cardiovascular disease with recent clinical advances.
  • Offers a contemporary, clinical focus based on a new understanding of underlying pathologies, as well as application of evidence from clinical trials that have dramatically changed treatment and affected both cardiology and endocrinology practice.
  • Includes state-of-the-art coverage of antihyperglycemic medications that have demonstrated efficacy to reduce risk for atherosclerotic cardiovascular disease, heart failure, and kidney disease progression, that have affected a revolution of therapy in both cardiology and endocrinology.
  • Features a practical, concise presentation with a focus on actionable clinical content, including new Clinical Practice Points and Take Home Summaries.
  • Any additional digital ancillary content may publish up to 6 weeks following the publication date.

1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Inside Front Cover - p. iii 6. Copyright - p. iv 7. Dedication - p. v 8. Contributors - p. vii 9. Foreword - p. xi 10. Preface - p. xiii 11. Acknowledgments - p. xv 12. Braunwald’s Heart Disease Family of Books - p. xviii 13. PART I: DIABETES MELLITUS - p. P1 14. 1. Definition and Epidemiology of Type 2 Diabetes Mellitus - p. 1 15. 2. Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights - p. 9 16. 3. Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus - p. 25 17. 4. Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes - p. 48 18. 5. Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease - p. 61 19. PART II: CARDIOVASCULAR COMPLICATIONS OFTYPE 2 DIABETES - p. P81 20. 6. Epidemiology of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease - p. 81 21. 7. Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes - p. 97 22. 8. Risk Stratification Among Patients With Type 2 Diabetes With or at Risk for Atherosclerotic Cardiovascular Disease - p. 131 23. 9. Epidemiology and Pathophysiology of Heart Failure With Preserved and With Reduced Ejection Fraction in Patients With Type 2 Diabetes - p. 142 24. PART III: EFFECTS OF ANTIHYPERGLYCEMIC THERAPIES FOR TYPE 2 DIABETES ON CARDIOVASCULAR AND KIDNEY OUTCOMES - p. P151 25. 10. Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 151 26. 11. Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future - p. 170 27. 12. Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors - p. 180 28. 13. Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists - p. 193 29. 14. Antihyperglycemic Medications With Proven Cardiovascular Safety - p. 204 30. 15. Prevention of Heart Failure in People With Diabetes - p. 217 31. 16. Treatment of Patients With Reduced and With Preserved Ejection Fraction Heart Failure in Patients With Type 2 Diabetes - p. 231 32. PART IV: MANAGEMENT OF CORONARY HEART DISEASE RISK CHRONIC AND ACUTE CORONARY SYNDROMES IN PATIENTS WITH TYPE 2 DIABETES - p. P245 33. 17. Effect of Lifestyle Interventions on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 245 34. 18. Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes - p. 260 35. 19. Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes - p. 273 36. 20. Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus - p. 284 37. 21. Role of Percutaneous Coronary Intervention in Patients With Diabetes - p. 297 38. PART V: OTHER CARDIOVASCULARCONSIDERATIONS FOR PATIENTS WITH TYPE 2 DIABETES - p. P309 39. 22. Peripheral Artery Disease in Persons With Type 2 Diabetes - p. 309 40. 23. Cerebrovascular Disease in Persons With Diabetes - p. 324 41. 24. Atrial Fibrillation in Persons With Type 2 Diabetes - p. 342 42. 25. Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes - p. 353 43. 26. Disparities in Type 2 Diabetes Risk, Cardiovascular Consequences, and Care: Females, Racial/Ethnic Minorities, and the Elderly - p. 369 44. 27. The Quality Chasm and the Need for Implementation Science to Reduce Cardiovascular Disease Risk in Type 2 Diabetes - p. 381 45. Index - p. 387 46. Inside Back Cover - p. 396

Indice
Autores
Muestra
Ficha Técnica